Panacea Index Logo

Command Palette

Search for a command to run...

Biological rhythms and chronotherapeutics in depression.

Progress in neuro-psychopharmacology & biological psychiatry
January 1, 1970
Pierre A Geoffroy et al. (2 authors)
Journal ArticleReviewHuman Study
Study Details

Study Goal

The researchers aimed to review theoretical and practical aspects of chronotherapeutics, including Light Therapy (LT), for treating depressive syndromes and improving sleep-related symptoms.

Results Summary

Light Therapy (LT) is effective as a first-line monotherapy for moderate to severe depression of all subtypes and enhances response rates when combined with antidepressants. It is also part of a triple chronotherapy approach, combining sleep deprivation, sleep phase advance, and LT for stabilizing antidepressant effects.

Population

Patients with unipolar or bipolar depression, particularly those with sleep complaints.

Effective Dosage

Not specified

Duration

Not specified

Interactions

Combination with antidepressants is mentioned to maximize response rates.

Extracted Claims (8)
InterventionDirectionEndpointPopulationDosageImpactClaim #
Light therapy (LT)
decrease
moderate to severe depression of all subtypes
-
-
can be used as a first-line monotherapy
#1
Light therapy (LT)
increase
patients' response rates
-
-
has a clear superiority
#2
Sleep deprivation (SD)
decrease
depression
patients with unipolar or bipolar depression
45-60%
is a rapid and powerful chronotherapeutic with antidepressant responses
#3
Melatonin treatment
decrease
relapses or recurrences
remitted patients with mood disorder
-
is of interest
#4
Melatonin
decrease
symptoms of insomnia associated with depression
-
-
could be used as an adjuvant treatment
#5
Cognitive behavioral therapy for insomnia (CBT-I)
decrease
insomnia
-
-
can be recommend to treat
#6
Interpersonal and social rhythm therapy (IPSRT)
decrease
bipolar depression
-
-
is indicated for the acute treatment
#7
Interpersonal and social rhythm therapy (IPSRT)
decrease
mood episodes
-
-
is indicated for the prevention
#8
Abstract

Depressive syndromes are frequent and heterogeneous brain conditions with more than 90% of patients suffering from sleep complaints. Better characterizing this "sleep" domain may allow to both better treat acute episodes with existing chronotherapeutics, but also to prevent the manifestation or recurrences of mood disorders. This work aims to i) review theoretical and fundamental data of chronotherapeutics, and ii) provide practical recommendations. Light therapy (LT) can be used as a first-line monotherapy of moderate to severe depression of all subtypes. LT can be also used as a combination with antidepressant to maximize patients' response rates, which has a clear superiority to antidepressant alone. Sleep deprivation (SD) is a rapid and powerful chronotherapeutic with antidepressant responses within hours in 45-60% of patients with unipolar or bipolar depression. Different strategies should be combined to stabilize the SD antidepressant effect, including concomitant medications, repeated SD, combination with sleep phase advance and/or LT (triple chronotherapy). Melatonin treatment is of interest in remitted patients with mood disorder to prevent relapses or recurrences, if a complaint of insomnia, poor sleep quality or phase delay syndrome is associated. During the acute phase, melatonin could be used as an adjuvant treatment for symptoms of insomnia associated with depression. The cognitive behavioral therapy for insomnia (CBT-I) can be recommend to treat insomnia during euthymic phases. The Interpersonal and social rhythm therapy (IPSRT) is indicated for the acute treatment of bipolar depression and for the prevention of mood episodes. Chronotherapeutics should always be associated with behavioral measures for healthy sleep.

Medical Subject Headings (MeSH)
AnimalsChronotherapyCircadian RhythmCognitive Behavioral TherapyDepressionDrug ChronotherapyHumansMelatoninPeriodicityPhototherapySleepSleep DeprivationSleep Initiation and Maintenance DisordersSleep Quality
Study Links
Quality Scores
SafetyNot Assessed
Efficacy85/10
Quality75/10
Citation Metrics
Total Citations45
Citations/Year11.3
Relative Citation Ratio4.60
NIH Percentile92.1%
Research Impact Scores
APT Score0.95
Weight Score0.89
Normalized Score0.69
Related Supplements